Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term access to guanfacine extended-release for European subjects with ADHD from SPD503-315 or SPD503-316
2011-004668-31Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Nov 2011; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2011-004668-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004668-31.